Ryan Bushey
Digital Editor

Ryan Bushey is a digital editor for Advantage Business Media’s Science Group.  He covers scientific discoveries, emerging technologies and the business of the life sciences sector for R&D Magazine and Drug Discovery & Development along with managing social media for both publications. He’s an experienced journalist whose work has appeared in Business Insider, Slate, and Indiewire.

Pfizer is getting closer to gaining regulatory approval for an investigational leukemia treatment called inotuzumab ozogamicin.
Digital Editor
|
2.22.2017
8:31am
British-based pharmaceutical firm AstraZeneca may be gaining an advantage in the burgeoning PARP inhibitor drug space.
Digital Editor
|
2.21.2017
8:19am
Boston-based Rhythm Pharmaceuticals obtained a new round of funding to help continue development of its lead peptide therapy setmelanotide.
Digital Editor
|
2.17.2017
8:40am
A promising multiple sclerosis treatment called Ocrevus will play a crucial role in this growth.
Digital Editor
|
2.16.2017
8:23am
Investigators will gain a five-year appointment and up to $1.5 million in funding to kick start their research projects.
Digital Editor
|
2.15.2017
8:41am
Advertisement
Another drug company reignited the debate over appropriate pricing policies for important medications.
Digital Editor
|
2.14.2017
9:06am
More than 150 biotech CEOS, venture capitalists and startup founders signed a letter to the President expressing their deep concern and opposition to the order.
Digital Editor
|
2.9.2017
7:59am
British-based GW Pharmaceuticals received more good news regarding its cannabis-based drug development efforts.
Digital Editor
|
2.8.2017
8:20am
Investigators running this randomized, double-blind, placebo-controlled trial recruited 150 elderly patients diagnosed with acute myeloid leukemia.
Digital Editor
|
2.6.2017
1:02pm
Bristol-Myers Squibb’s prized immuno-oncology drug gained another label expansion.
Digital Editor
|
2.3.2017
9:42am
Another drug company unveiled a new strategy for dealing with the drug pricing debate.
Digital Editor
|
2.2.2017
9:28am
The government is working on new strategies to ensure pharmaceutical and biotech R&D can thrive in the country after the process is completed.
Digital Editor
|
1.27.2017
9:04am
The lobbying group began laying the groundwork for this program several months ago in the midst of the election.
Digital Editor
|
1.26.2017
10:22am
Advertisement
Celgene expanded its autoimmune disease pipeline with a new acquisition.
Digital Editor
|
1.26.2017
10:20am
MDX has traversed a difficult path during the research and development process.
Digital Editor
|
1.18.2017
7:42am
President-elect Donald Trump went after the pharmaceutical industry in the opening remarks of his first press conference since the election.
Digital Editor
|
1.12.2017
8:32am
The Cambridge, Massachusetts-based biotech company has kept its pipeline a secret until now.
Digital Editor
|
1.11.2017
9:52am
Japanese drugmaker Takeda acquired Boston-based Ariad Pharmaceuticals, a biotech company specializing in cancer drugs.
Digital Editor
|
1.10.2017
8:34am
The biotech startup wants to use this new funding to advance development of its specialized early detection cancer test.
Digital Editor
|
1.9.2017
8:29am
The Foster City, California-based biotech added a top cancer specialist to its executive ranks.
Digital Editor
|
1.5.2017
8:35am
An analysis published by Deloitte’s Centre for Health Solutions indicated the pharmaceutical industry experienced a continued decline in R&D returns for...
Digital Editor
|
1.3.2017
8:37am
Advertisement
Other researchers have used similar methods to sift through large amounts of data in order to pinpoint promising compounds to treat diseases.
Digital Editor
|
12.30.2016
11:08am
These articles provide a snapshot of the change the pharmaceutical industry experienced throughout the year.
Digital Editor
|
12.21.2016
8:30am
A new report explains how hospitals are implementing aggressive new measures to cut pharmaceutical spending in the face of rapidly rising prices for certain...
Digital Editor
|
12.20.2016
8:29am
Novartis is bolstering its dermatology portfolio with a new acquisition.
Digital Editor
|
12.19.2016
8:18am
Voyager Therapeutics is testing an experimental gene therapy that could boost Parkinson’s patients’ responses to levodopa.
Digital Editor
|
12.15.2016
9:00am
Eli Lilly will launch a new program in conjunction with Express Scripts to offer diabetes patients lower prices for its insulin products.
Digital Editor
|
12.13.2016
2:16pm
Bayer in conjunction with Versant Ventures are investing up to $225 million in a startup called Bluerock Therapeutics in one of the largest Series A funding...
Digital Editor
|
12.13.2016
8:16am
Biogen reported more encouraging data for its experimental Alzheimer’s treatment aducanumab on Thursday.
Digital Editor
|
12.12.2016
8:14am
The transition team for President-elect Donald Trump is reportedly exploring an unusual pick to run the Food and Drug Administration.
Digital Editor
|
12.9.2016
10:46am
Part of this restructuring process will include cutting less than 10 percent of its global workforce.
Digital Editor
|
12.8.2016
8:24am
Heather Bresch came to the fifth annual Forbes Healthcare conference to talk about the fallout from the EpiPen pricing controversy.
Digital Editor
|
12.5.2016
8:29am
This condition produces mutations that lead to a serious shortage of white blood cells.
Digital Editor
|
11.30.2016
8:32am
Approximately 400,000 people all over the world are living with either hemophilia A or hemophilia B.
Digital Editor
|
11.29.2016
9:58am
An experimental Alzheimer’s drug being developed by Eli Lilly failed to slow cognitive decline in patients with even a mild form of the condition.
Digital Editor
|
11.28.2016
8:50am
Novartis is boosting its hematology pipeline with a new acquisition.
Digital Editor
|
11.22.2016
9:51am
Amgen and Novartis are one step closer to having a contender in the migraine treatment space.
Digital Editor
|
11.17.2016
10:01am
Amgen announced good news for its cholesterol drug Repatha at the annual American Heart Association meeting taking place in New Orleans.
Digital Editor
|
11.16.2016
8:35am
Drug makers are working with companies like Propeller Health on these devices because they could provide improved adherence and better health outcomes.
Digital Editor
|
11.14.2016
8:29am